European Biotech Acquisition - Warrants (06/03/2026) Accounts Payable

As of the most recent data (December 2022), EBACW shows a accounts payable of $360K. That compares with $58K in the prior-year period — up 520.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EBACW's accounts payable is now $360K (was $58K) — a 520.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether European Biotech Acquisition - Warrants (06/03/2026) is outperforming or lagging.

Tracking EBACW's accounts payable over time shows whether European Biotech Acquisition - Warrants (06/03/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $360K That compares with $58K in the prior-year period — up 520.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has European Biotech Acquisition - Warrants (06/03/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $360K) with ownership activity and broader fundamentals.